These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298 [TBL] [Abstract][Full Text] [Related]
9. An assessment of the Frewen regime in the treatment of detrusor dysfunction in females. Elder DD; Stephenson TP; Bary PR Prog Clin Biol Res; 1981; 78():321-8. PubMed ID: 7335747 [TBL] [Abstract][Full Text] [Related]
10. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Kuo HC Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967 [TBL] [Abstract][Full Text] [Related]
11. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014 [TBL] [Abstract][Full Text] [Related]
12. Defining overactive bladder: epidemiology and burden of disease. Tubaro A Urology; 2004 Dec; 64(6 Suppl 1):2-6. PubMed ID: 15621220 [TBL] [Abstract][Full Text] [Related]
13. Variability of detrusor overactivity on repeated filling cystometry in men with urge symptoms: comparison with spinal cord injury patients. Ockrim J; Laniado ME; Khoubehi B; Renzetti R; Finazzi Agrò E; Carter SS; Tubaro A BJU Int; 2005 Mar; 95(4):587-90. PubMed ID: 15705085 [TBL] [Abstract][Full Text] [Related]
14. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Ransmayr GN; Holliger S; Schletterer K; Heidler H; Deibl M; Poewe W; Madersbacher H; Kiss G Neurology; 2008 Jan; 70(4):299-303. PubMed ID: 18209204 [TBL] [Abstract][Full Text] [Related]
15. A prospective assessment of overactive bladder symptoms in a cohort of elderly women who underwent transvaginal surgery for advanced pelvic organ prolapse. Foster RT; Barber MD; Parasio MF; Walters MD; Weidner AC; Amundsen CL Am J Obstet Gynecol; 2007 Jul; 197(1):82.e1-4. PubMed ID: 17618768 [TBL] [Abstract][Full Text] [Related]
16. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity. Bach P; Wormland RT; Möhring C; Goepel M Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067 [TBL] [Abstract][Full Text] [Related]
17. The relationship between urinary symptom questionnaires and urodynamic diagnoses: an analysis of two methods of questionnaire administration. Khan MS; Chaliha C; Leskova L; Khullar V BJOG; 2004 May; 111(5):468-74. PubMed ID: 15104612 [TBL] [Abstract][Full Text] [Related]
18. Relationships between micturition urgency and involuntary voiding dynamics in men with urinary incontinence from idiopathic detrusor overactivity. Cucchi A; Quaglini S; Rovereto B J Urol; 2007 Aug; 178(2):563-7; discussion 567. PubMed ID: 17570436 [TBL] [Abstract][Full Text] [Related]
19. Dysfunctional voiding and urodynamic disorders in children with recurrent urinary tract infection. Zajaczkowska M; Moulhee NM; Piechuta L; Majewski M; Borzecka H Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):385-91. PubMed ID: 16146114 [TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF; J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]